Skip to content

Study · Measured the body's own peptide · 1992

2 results

Appearance of thymosin alpha 1 in supernatants of monocytes incubated with prothymosin alpha.

Frillingos S, Seferiadis K, Papanastasiou M, Baxevanis CN, Frangou-Lazaridis M, Economou M, Papamichail M, Tsolas O

Archives of biochemistry and biophysics1 Jul 1992Cited by 10 (Europe PMC)

PMID1534980 (opens in a new tab)DOI10.1016/0003-9861(92)90570-m (opens in a new tab)PepBankPUB-01534980
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelIn vitro (cells)Mechanism

    In human blood monocytes, incubation with prothymosin alpha led to release of the body's own thymosin alpha‑1 into the culture supernatant.

    In plain wordsIn human cells in a dish, adding prothymosin alpha made the cells release their own thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseRelease of thymosin alpha 1 into monocyte supernatants after prothymosin alpha
    Study

    humann: not reported in source

    Human peripheral blood monocytes
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Human peripheral blood monocytes incubated with prothymosin alpha release thymosin alpha 1 in the culture supernatants.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02LabEndogenous levelIn vitro (cells)Mechanism

    In human blood monocytes, release of thymosin alpha‑1 involved de novo protein synthesis and was inhibited by actinomycin D and cycloheximide.

    In plain wordsIn human cells in a dish, blocking protein synthesis stopped the cells releasing their own thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDependence of thymosin alpha 1 release on protein synthesis
    Study

    humann: not reported in source

    Human peripheral blood monocytes
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The production of thymosin alpha 1 involves de novo protein synthesis as shown by the kinetics of this release and its inhibition by actinomycin D and cycloheximide.
    1 context sentence
    Summary · context
    Human peripheral blood monocytes incubated with prothymosin alpha release thymosin alpha 1 in the culture supernatants.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.